Jiangsu Hengrui Medicine was approved by the FDA for US marketing of oxalipatin, a generic treatment for colon and rectum cancer. Hengrui, whose major focus is chemotherapies, has annual revenues of $1 billion. The company said the latest US approval is part of its globalization initiative. Hengrui already markets oxaliplatin in China and Europe.
Help employers find you! Check out all the jobs and post your resume.
